Physiological actions of angiotensin II mediated by AT1 AND AT2 receptors in the brain. 1996

M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Parkville, Victoria, Australia.

1. Autoradiographic binding studies have shown that the AT(1) receptor is the predominant angiotensin II (AngII) receptor subtype in the central nervous system (CNS). Major sites of AT(1) receptors are the lamina terminalis, hypothalamic paraventricular nucleus, the lateral parabrachial nucleus, rostral and caudal ventrolateral medulla, nucleus of the solitary tract and the intermediolateral cell column of the thoraco-lumbar spinal cord. 2. While there are differences between species, AT(2) receptors are found mainly in the cerebellum, inferior olive and locus coeruleus of the rat. 3. Circulating AngII acts on AT(1) receptors in the subfornical organ and organum vasculosum of the lamina terminalis (OVLT) to stimulate neurons that may have a role in initiating water drinking. 4. Centrally administered AngII may act on AT(1) receptors in the median preoptic nucleus and elsewhere to induce drinking, sodium appetite, a sympathetic vasoconstrictor response and vasopressin secretion. 5. Recent evidence shows that centrally administered AT(1) antagonists inhibit dipsogenic, natriuretic, pressor and vasopressin secretory responses to intracerebroventricular infusion of hypertonic saline. This suggests that an angiotensinergic neural pathway has a role in osmoregulatory responses. 6. Central angiotensinergic pathways which include neural inputs to the rostral ventrolateral medulla may use AT(1) receptors and play a role in the function of sympathetic pathways maintaining arterial pressure.

UI MeSH Term Description Entries
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D044139 Receptor, Angiotensin, Type 2 An angiotensin receptor subtype that is expressed at high levels in fetal tissues. Many effects of the angiotensin type 2 receptor such as VASODILATION and sodium loss are the opposite of that of the ANGIOTENSIN TYPE 1 RECEPTOR. Angiotensin II Type 2 Receptor,Angiotensin Type 2 Receptor,Receptor, Angiotensin II Type 2,Angiotensin AT2 Receptor,AT2 Receptor, Angiotensin,Receptor, Angiotensin AT2
D044140 Receptor, Angiotensin, Type 1 An angiotensin receptor subtype that is expressed at high levels in a variety of adult tissues including the CARDIOVASCULAR SYSTEM, the KIDNEY, the ENDOCRINE SYSTEM and the NERVOUS SYSTEM. Activation of the type 1 angiotensin receptor causes VASOCONSTRICTION and sodium retention. Angiotensin II Type 1 Receptor,Angiotensin Type 1 Receptor,Angiotensin Type 1a Receptor,Angiotensin Type 1b Receptor,Receptor, Angiotensin, Type 1a,Receptor, Angiotensin, Type 1b,Angiotensin AT1 Receptor,Angiotensin AT1a Receptor,Angiotensin AT1b Receptor,Angiotensin II Type 1a Receptor,Angiotensin II Type 1b Receptor,Receptor, Angiotensin II Type 1,Receptor, Angiotensin II Type 1a,Receptor, Angiotensin II Type 1b,AT1 Receptor, Angiotensin,AT1a Receptor, Angiotensin,AT1b Receptor, Angiotensin,Receptor, Angiotensin AT1,Receptor, Angiotensin AT1a,Receptor, Angiotensin AT1b

Related Publications

M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
December 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
October 1997, Japanese circulation journal,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
May 2006, Histology and histopathology,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
February 1993, Brain research,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
January 1999, Journal of the American Society of Nephrology : JASN,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
January 1996, Blood pressure. Supplement,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
January 2005, Regulatory peptides,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
August 1997, The American journal of physiology,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
March 1998, Journal of cardiovascular pharmacology,
M J McKinley, and R M McAllen, and G L Pennington, and A Smardencas, and R S Weisinger, and B J Oldfield
July 1998, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!